Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL865549 | 0.83 | IDO1 (0.68) | IDO1NPC1CYP2D6ALDH1A1CYP2C19 | |
| SCHEMBL30873130 | 0.83 | IDO1 (0.68) | IDO1NPC1CYP2D6ALDH1A1CYP2C19 | |
| SCHEMBL14101048 | 0.83 | PNMT (0.50) | IDO1CYP2D6ALDH1A1CYP2C19PNMT | |
| SCHEMBL6236937 | 0.82 | IDO1 (0.57) | IDO1NPC1CYP2D6ALDH1A1CYP2C19 | |
| SCHEMBL10458219 | 0.81 | IDO1 (0.55) | IDO1NPC1CYP2D6ALDH1A1CYP2C19 | |
| SCHEMBL1179916 | 0.81 | IDO1 (0.55) | IDO1NPC1CYP2D6ALDH1A1CYP2C19 | |
| SCHEMBL12885103 | 0.81 | IDO1 (0.55) | IDO1NPC1CYP2D6ALDH1A1CYP2C19 | |
| SCHEMBL7228371 | 0.79 | IDO1 (0.53) | IDO1NPC1CYP2D6ALDH1A1CYP2C19 | |
| SCHEMBL21483755 | 0.79 | TSHR (0.43) | IDO1NPC1ALDH1A1RAB9AMAPT | |
| SCHEMBL27940425 | 0.78 | IDO1 (0.56) | IDO1NPC1CYP2D6ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| EP-2124941-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | Argenta Discovery Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008096136-A1 | COMBINATIONS WITH A MUSCARINIC RECEPTOR ANTAGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096136-A1 | COMBINATIONS WITH A MUSCARINIC RECEPTOR ANTAGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096126-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096126-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096093-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AND THEIR USES | ARGENTA DISCOVERY LTD. (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096093-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AND THEIR USES | ARGENTA DISCOVERY LTD. (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008023157-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS USEFUL AS M3-RECEPTOR MODULATORS | ARGENTA DISCOVERY LIMITED (GB) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ADRB2, ADRB1, ADRA2A | IDO1 1005/4885NPC1 2438/4885CYP2D6 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.